Posted by Michael Wonder on 07 Apr 2020
Blaze Bioscience announces FDA has granted fast track designation to BLZ-100 (tozuleristide) for paediatric central nervous system tumours
7 April 2020 - Phase 2/3 pivotal trial ongoing in patients up to 30 years of age undergoing surgery for paediatric central nervous system tumours.
Blaze Bioscience, Inc., the Tumor Paint Company, announced today that its clinical program evaluating tozuleristide (BLZ-100) for paediatric brain tumours, has been granted fast track designation from the U.S. FDA.
BLZ-100 (tozuleristide) is the first product candidate from Blaze’s Tumor Paint platform and consists of a targeting peptide and a fluorescent dye, which emits light in the near-infrared range.
